Literature DB >> 8783669

Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity.

A F List1, R Heaton, B Glinsmann-Gibson, R L Capizzi.   

Abstract

Controlled clinical trials indicate that amifostine (WR-2721, Ethyol) confers protection from the cumulative hematologic toxicities associated with alkylating agents and organoplatinums. To determine whether amifostine protects primitive hematopoietic progenitors from the cytotoxicity of functionally diverse antineoplastics, formation of the multipotent hematopoietic progenitors colony-forming units-granulocyte-erythroid, macrophage, megakaryocyte (CFU-GEMM) and erythroid burst-forming units (BFU-E) was evaluated using a clonogenic progenitor inhibition assay. Bone marrow mononuclear cells from normal donors were subjected to a 15-minute exposure of medium, amifostine (500 micromol/L), or WR-1065 (100 micromol/L at concentrations approximating peak plasma levels, washed twice, then treated with the antineoplastic for 1 to 6 hours. Colony growth was scored after 14 days of incubation. Amifostine conferred protection against a broader range of antineoplastics than did WR-1065. Amifostine protected CFU-GEMM against cytotoxicity from daunorubicin, mitoxantrone, and paclitaxel (range, 1.29- to 9.57-fold) (P < .05) but did not afford protection against cisplatin, diaziquone, or thiotepa. Similarly, amifostine protected BFU-E against toxicity from doxorubicin, mitoxantrone, paclitaxel, cisplatin, and diaziquone, yielding 3.4- to 65-fold greater colony recovery compared with controls. The high degree of cytoprotection afforded by amifostine derived largely from stimulation of progenitor growth at sublethal chemotherapy concentrations. In the absence of antineoplastic exposure, preincubation with amifostine or WR-1065 enhanced the colony-forming capacity of bone marrow progenitors from six normal donors, increasing recovery of CFU-GEMM and BFU-E up to sevenfold. We conclude that amifostine protects primitive hematopoietic progenitors from a wide range of antineoplastics. This broad hemoprotective effect derives in part from inherent trophic effects on progenitor growth and survival.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8783669

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  10 in total

1.  Effect of Imatinib Coadministration on in Vitro Oocyte Acquisition and Subsequent Embryo Development in Cyclophosphamide-Treated Mice.

Authors:  Eun Kyung Chun; Byung Chul Jee; Ju Yeong Kim; Seok Hyun Kim; Shin Yong Moon
Journal:  Reprod Sci       Date:  2014-01-08       Impact factor: 3.060

Review 2.  Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.

Authors:  K Hoekman; W J van der Vijgh; J B Vermorken
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

Review 3.  Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.

Authors:  C R Culy; C M Spencer
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 4.  Oxidative stress, redox regulation and diseases of cellular differentiation.

Authors:  Zhi-Wei Ye; Jie Zhang; Danyelle M Townsend; Kenneth D Tew
Journal:  Biochim Biophys Acta       Date:  2014-11-15

5.  Neuroprotection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel-based chemotherapy--a double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynäkologische Onkologoie (AGO) Ovarian Cancer Study Group.

Authors:  F Hilpert; A Stähle; O Tomé; A Burges; D Rossner; K Späthe; V Heilmann; B Richter; A du Bois
Journal:  Support Care Cancer       Date:  2005-07-16       Impact factor: 3.603

Review 6.  The impact of redox and thiol status on the bone marrow: Pharmacological intervention strategies.

Authors:  Christina L Grek; Danyelle M Townsend; Kenneth D Tew
Journal:  Pharmacol Ther       Date:  2010-10-15       Impact factor: 12.310

Review 7.  Oxidative stress and the myelodysplastic syndromes.

Authors:  Morag J Farquhar; David T Bowen
Journal:  Int J Hematol       Date:  2003-05       Impact factor: 2.490

8.  Pre-treatment with amifostine protects against cyclophosphamide-induced disruption of taste in mice.

Authors:  Nabanita Mukherjee; Brittany L Carroll; Jeffrey L Spees; Eugene R Delay
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

9.  Amifostine reduces the seminiferous epithelium damage in doxorubicin-treated prepubertal rats without improving the fertility status.

Authors:  Vanessa Vendramini; Estela Sasso-Cerri; Sandra M Miraglia
Journal:  Reprod Biol Endocrinol       Date:  2010-01-10       Impact factor: 5.211

10.  In vitro effect of amifostine on haematopoietic progenitors exposed to carboplatin and non-alkylating antineoplastic drugs: haematoprotection acts as a drug-specific progenitor rescue.

Authors:  L Pierelli; G Scambia; A Fattorossi; G Bonanno; A Battaglia; A Perillo; G Menichella; P B Panici; G Leone; S Mancuso
Journal:  Br J Cancer       Date:  1998-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.